AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly EVP buys 1,000 shares at $647.36 on Aug. 13, 2025.
ByAinvest
Wednesday, Aug 13, 2025 5:10 pm ET1min read
Eli Lilly & Company reports that Van Naarden Jacob, Executive Vice President and President of Lilly Oncology, has made a recent investment in the company. On August 13, 2025, Jacob acquired 1000 shares at a price of $647.36 per share.
Title: Eli Lilly & Co. Reports Insider Investment by Van Naarden JacobEli Lilly & Company (NYSE: LLY) has disclosed that Van Naarden Jacob, Executive Vice President and President of Lilly Oncology, made a significant investment in the company. According to a recent SEC Form 4 filing [1], Jacob acquired 1000 shares of Eli Lilly's common stock on August 13, 2025, at a price of $647.36 per share. This purchase brought his total beneficial ownership to 20,561.985 shares.
This investment comes amidst a period of strategic growth and market expansion for Eli Lilly. The company has recently launched its best-selling diabetes drug, Mounjaro, in a new injector pen format in India, intensifying its competition with Novo Nordisk in the GLP-1 market [2]. Despite the strong financial performance reported in the second quarter of 2025, investor sentiment was affected by disappointing clinical trial data for Orforglipron, a weight loss drug candidate [3].
Eli Lilly faces ongoing challenges, including a lawsuit from the Texas Attorney General accusing the company of bribing healthcare providers to prescribe its medications, particularly GLP-1 drugs Mounjaro and Zepbound [3]. Despite these challenges, analysts maintain varying perspectives on the company's future, with some retaining positive outlooks due to the growth potential in the GLP-1 market [3].
References
1. [SEC Form 4](https://www.stocktitan.net/sec-filings/LLY/form-4-eli-lilly-co-insider-trading-activity-b52731b8b048.html)
2. [Eli Lilly Launches Mounjaro in India](https://finance.yahoo.com/news/eli-lilly-fires-glp-1-174856833.html)
3. [Guggenheim Lowers Price Target on Eli Lilly](https://www.investing.com/news/analyst-ratings/guggenheim-lowers-eli-lilly-stock-price-target-on-glp1-market-uncertainty-93CH-4188209)
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet